Page 1

EXHIBIT 99.1 UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2026 Contact : Brian Koopman ( 801 ) 566-1200 October 22 , 2026 Salt Lake City , Utah – Utah Medical Products , Inc. [ Nasdaq : UTMD ] reports third quarter ( 3Q ) and first nine months ( 9M ) of calendar year 2026 financial results that include changes from the prior year's same period results . Currencies in this release are denoted as $ or USD = U.S. Dollars ; AUD = Australia Dollars ; £ or GBP = UK Pound Sterling ; C $ or CAD = Canadian Dollars ; and € or EUR = Euros . Currency amounts throughout this report are in thousands , except per share amounts and where noted . Overview of Results The following is a summary comparison of 3Q and 9M of calendar 2026 with 3Q and 9M 2025 income statement measures : 2026 to 2025 Comparison Revenues ( Sales ) : Gross Profit ( GP ) : Operating Income ( OI ) : Income Before Tax ( EBT ) : Net Income ( NI ) : Earnings Per Share ( EPS ) : 3Q ( July - September ) 9M ( January - September ) ( 12 % ) ( 12 % ) ( 14 % ) ( 11 % ) + 7 % ( 11 % ) + 3 % ( 10 % ) + 6 % ( 7 % ) + 7 % ( 5 % ) In brief , consolidated total 3Q 2026 revenues were $ 1,191 ( 12.1 % ) lower than in 3Q 2025 , and 9M 2026 revenues were $ 3,602 ( 12.1 % ) lower than in 9M 2025. The lower sales in comparison with the prior year's periods were substantially a result of a lack of any 2026 sales to UTMD's two previously largest customers , PendoTECH , a supplier of control devices to biopharm manufacturing companies , and UTMD's distributor of disposable blood pressure monitoring ( BPM ) transducer kits in China . Those two lost customers in 2026 represented a combined $ 491 in 3Q 2025 sales , and a combined $ 2,419 in 9M 2025 sales . Partly offsetting the PendoTECH lost sales , UTMD realized $ 116 in 3Q 2026 sales , and $ 327 in 9M 2026 sales , to new biopharm customers . However , the 2026 growth in new biopharm sales has been slower than expected . Also , UTMD realized $ 195 in 3Q 2026 sales to a new China BPM kit distributor for the first time since losing the prior distributor a year ago . This distributor might eventually match the prior distributor's demand . There was also an accelerated decline in worldwide ( WW ) sales of the Filshie Clip System ( Filshie ) in 3Q 2026 , which were $ 805 ( 32.7 % ) lower than in 3Q 2025. The poor 3Q Filshie sales caused 9M 2026 Filshie sales to be $ 1,194 ( 15.7 % ) lower than in 9M 2025. On the other hand , Femcare Ltd , UTMD's subsidiary in the UK which developed the Filshie Clip System , acquired Orion Medical Supplies Ltd in the UK at the end of August 2026 , which added $ 619 in 3Q 2026 sales . Changes in period - to - period foreign currency exchange rates had less than a one percentage point impact on USD sales : 3Q 2026 sales were $ 14 lower , and 9M 2026 sales were $ 170 higher , than would have been the case with the same exchange rates in 2025. Further details about UTMD's period - to - period sales comparisons are provided later in this press release , and will also be explained in UTMD's public 3Q 2026 SEC 10 - Q disclosure in November .